Pharma BD Deal Intelligence
The three acquired oncology drug candidates all failed to show clinical efficacy; the only lasting value was the Boulder talent base OSI later leaned on for Tarceva, before shuttering the site in 2009.
Full analysis, sources & comparables →Gilead announced sale of its Boulder oncology pipeline and operations to OSI for up to $200M ($130M cash + $40M stock at close + up to $30M in…
Closing announcement: OSI paid $130M cash + 924,984 shares; acquired three next-generation cytotoxic candidates plus Gilead's Boulder R&D site. Lead asset…
Phase II of OSI-211 (liposomal lurtotecan) in topotecan-resistant ovarian cancer reported limited single-agent activity, foreshadowing the eventual…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Asset purchase: $130M cash + $40M OSI stock + up to $30M milestones (NX211). Acquired Gilead's Boulder oncology pipeline/site. Up to $200M total.
The three acquired oncology drug candidates all failed to show clinical efficacy; the only lasting value was the Boulder talent base OSI later leaned on for Tarceva, before shuttering the site in 2009.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| OSI Pharmaceuticals / Gilead Sciences (oncology assets) (this deal) | 2001 | $200M | 28 |
| OSI Pharmaceuticals / EyeTech Pharmaceuticals Inc. | 2005 | $935M | 10 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
← Browse all deals · How we score deals
More: 2001 deals